

- Mononuclear phagocyte system, in chronic inflammation, 94
- Mononucleosis, cytomegalovirus, 360
- Monosodium urate (MSU) crystals, 1215
- Monosomy, 159
- Morgagnian cataract, 1327
- Morton neuroma, 1234
- Mosaicism, 159-160
- Motor unit, 1227
- Mott cells, 394b
- MUC5B gene, 685
- Mucins, as tumor antigens, 312
- Mucinous carcinoma, of breast, 1065, 1065f
- Mucinous cystic neoplasms, of pancreas, 890-891, 891f
- Mucinous tumors, of ovaries, 1026-1027, 1026b, 1027f
- Mucocele, of salivary glands, 743, 743f
- Mucocutaneous leishmaniasis, 393b-394b
- Mucoepidermoid carcinoma, 745-746, 746b, 746f, 1323
- Mucopolysaccharidoses (MPSs), 154-155, 154b-155b, 1187
- Mucormycosis, 389-390, 389b-390b, 389f
- orbital inflammatory condition, 1320-1321
- Muir-Torre syndrome, 1156f
- Müllerian ducts, 992, 992f
- Müllerian-inhibiting substance, in cryptorchidism, 972-973
- Müllerian tumors, in ovaries, 1023-1029
- Müller's muscle, 1084
- Multicystic encephalopathy, 1259, 1259f
- Multicystic renal dysplasia, 949, 949f
- Multidrug resistance (MDR) protein, 9
- Multifactorial inheritance, congenital anomalies due to, 455
- Multilobular meningioma, 1315f
- Multinodular goiter, 1091-1092, 1092b, 1092f
- Multinucleated giant cells, in HIV encephalitis, 1278b
- Multiple endocrine neoplasia, type-1 (MEN-1), in parathyroidism, 1101, 1136
- Multiple endocrine neoplasia, type-2 (MEN-2), 1137
- in parathyroidism, 1101
- in pheochromocytoma, 1134t
- Multiple endocrine neoplasia, type 2B (MEN-2B), 1134t
- Multiple endocrine neoplasia syndromes, 1136-1137
- Multiple hereditary exostosis syndrome, 1200
- Multiple myeloma, 591t, 598-599, 599b, 600f, 602b
- morphology of, 601b
- Multiple sclerosis (MS), 209t, 1283-1285, 1284b-1285b, 1284f, 1285f
- HLA alleles and, 215t
- Multiple system atrophy (MSA), 1296-1297, 1297f
- Multiplex ligation-dependent probe amplification (MLPA), 177
- Multipotent progenitors, 581
- Mumps, 355-356, 356b
- epididymitis and orchitis due to, 974
- Mural thrombus, due to myocardial infarction, 549
- Muscle, 1227-1250
- in sarcoidosis, 693b-694b
- Muscleblind-like-1, 1244
- Muscular arteries, 484
- Muscular dystrophies, 1242-1244
- congenital, 1236
- Musculoskeletal system, in systemic sclerosis, 229b
- Mutated genes, products of, as tumor antigens, 310
- Mutation(s), 138-139
- in cancer, 319t
- within coding sequences, 138
- due to deletions and insertions, 139, 139f
- frameshift, 139, 139f
- gain-of-function, 141
- missense, 138
- within noncoding sequences, 138
- nonsense, 138, 138f
- point, 138, 138f
- trinucleotide-repeat, 139, 168-171, 168t, 169f
- MX1 gene, expression of, 706
- Myasthenia gravis, 206t, 1235-1236
- in antibody-mediated hypersensitivity, 205
- Myasthenia gravis, due to cancer, 331
- MYC oncogene, 288, 301
- Mycobacterial arthritis, 1214
- Mycobacterial infections, 371-378
- Mycobacterial osteomyelitis, 1196
- Mycobacterium avium* complex, 376-377, 377b, 377f
- Mycobacterium leprae*, 377
- Mycoplasma hominis*, 994
- Mycoplasmas, sexually transmitted infections, 351t
- Mycosis fungoides, 591t, 605-606
- Myelin figures, in cell injury, 50-51
- Myelodysplasia, 615f
- Myelodysplastic syndromes (MDS), 586, 614-616, 621b
- morphology of, 615b
- Myelogenous leukemia, chronic, oncogenes for, 287, 287f
- Myeloid neoplasms, 586, 611-621, 621b
- Myeloid tissues, 579
- Myeloma kidney, 599b, 937-938
- Myelomeningocele, 1256
- Myeloperoxidase (MPO), in phagocytosis, 79
- Myelophthisic anemia, 655
- Myeloproliferative disorders, 616-621, 621b
- tyrosine kinase mutations in, 616t
- MYH9-USP6 fusion gene, 1221
- Myocardial disease
- due to amyloidosis, 571-573, 573f
- due to cardiotoxic drugs, 571
- Myocardial hypertrophy, 33f, 35f
- Myocardial infarction (MI), 540-549, 543b-545b
- acute, and thrombosis, 123
- clinical features of, 547, 547f
- consequences and complications of, 547-549, 548f
- expansion of, 549
- extension of, 555
- incidence and risk factors of, 540
- pathogenesis of, 540-549
- perfusion of, 545-547, 546f
- reversible vs. irreversible, 541f, 544t, 546f
- right ventricular, 568
- subendocardial, 543
- transmural, 540, 543
- triphenyltetrazolium chloride in, 544-545, 544f
- Myocardial irritability, due to myocardial infarction, 549
- Myocardial ischemia. *See also* Ischemic heart disease (IHD)
- causes of, 538
- consequences of, 539, 545f, 546f
- coronary artery occlusion due to, 540
- reversible vs. irreversible, 541f, 544t, 546f
- temporal progression of, 541, 541f, 541t
- Myocardial natriuretic peptides, 489-490
- Myocardial necrosis, progression of, 542f
- Myocardial response, to coronary artery obstruction, 540-542, 541f, 541t
- Myocardial rupture, due to myocardial infarction, 548f, 549
- Myocardial vessel vasospasm, 514
- Myocarditis, 570-571, 571b, 571t, 572f
- lethal acute, 395b
- Myocardium, 524
- hibernation, 547
- preconditioning, 547
- stunned, 547
- Myoclonic epilepsy and ragged red fibers (MERRF), 1304
- Myocytolysis, in myocardial infarction, 545
- Myofibroblastoma, of breast, 1070
- Myofibroblasts, 105, 108
- Myometrium
- leiomyoma of, 275f
- tumors of
- leiomyomas, 1019-1020, 1020b, 1020f
- leiomyosarcomas, 1020-1021, 1020b-1021b, 1021f
- Myophagocytosis, 1237-1238
- Myophosphorylase deficiency, 1244
- Myosin, in myocardium, 524
- Myosin deficient myopathy, 1240-1241
- Myositis, autoimmune, autoantibodies in, 219t
- Myotonic dystrophy, 1243-1244
- Myxedema, 1086
- pretibial, 1089
- Myxoid liposarcoma, 1220b, 1221f
- Myxomas, cardiac, 575, 575b-576b, 575f
- Myxomatous degeneration, of mitral valve, 556, 557f
- Myxopapillary ependymomas, 1310b-1311b
- N**
- Nail changes, due to psoriasis, 1165b-1166b
- Nail-patella syndrome, 1184t
- Nail plate, 1165
- 2-Naphthylamine, and bladder cancer, 964-965
- Nasal polyps, 735, 736f
- Nasopharyngeal angiofibroma, 737
- Nasopharyngeal carcinoma, 737-738, 738f
- Epstein-Barr virus in, 328
- Nasopharynx
- disorders of, 736
- inflammations of, 736
- tumors of, 737-738
- Native immunity, 186
- Natural immunity, 186
- Natural killer cells
- antitumor effect of, 312
- in immune response, 187, 192, 192f, 199b-200b
- Neck, disorders of, 741-742
- Necroptosis, 58-59, 60b
- TNF-mediated, 59f